Table 2. Percentage of subjects with growth inhibition assay activity ≥15% against 3D7 parasites, and percentage seroconverting from below up to or above threshold 30 days after last vaccination and at one and two years after enrollment, by vaccine group.
| Vaccine Group | |||
|---|---|---|---|
| Time point | AMA1 (%) | Control (%) | p-value1 |
| Day 0 | 32/199 (16.1) | 31/201 (15.4) | 0.86 |
| Day 30 | 15/194 (7.7) | 16/195 (8.2) | 0.86 |
| Day 60 | 57/190 (30.0) | 25/191 (13.1) | <0.00012 |
| Day 90 | 97/195 (49.7) | 30/192 (15.6) | <0.00012 |
| Day 150 | 65/194 (33.5) | 21/189 (11.1) | <0.00012 |
| Day 240 | 35/192 (18.2) | 12/189 (6.3) | 0.00042 |
| Day 364 | 24/191 (12.6) | 9/187 (4.8) | 0.008 |
| Day 547 | 60/187 (32.1) | 27/185 (14.6) | <0.00012 |
| Day 730 | 32/181 (17.7) | 13/177 (7.3) | 0.0032 |
| Day 0 <15%GIA; Day 90 ≥15%GIA | 75/163 (46.0) | 23/163 (14.1) | <0.00012 |
| Day 0 <15%GIA; Day 364 ≥15%GIA | 16/160 (10.0) | 7/159 (4.4) | 0.053 |
| Day 0 <15%GIA; Day 730 ≥15%GIA | 26/155 (16.8) | 10/151 (6.6) | 0.006 |
1 Two-sided t-test
2 p ≤ α* = 1–0.951/12 = 0.00427; assuming all 12 tests are independent, testing at significance level α* keeps the overall type I error rate at 0.05.